Radiolabeling fingolimod with technetium-99 m and evaluating its biological affinity by in vitro method
| dc.contributor.author | Uygur, E | |
| dc.contributor.author | Parlak, Y | |
| dc.contributor.author | Karatay, KB | |
| dc.contributor.author | Sezgin, C | |
| dc.contributor.author | Gümüser, FG | |
| dc.contributor.author | Müftüler, FZB | |
| dc.date.accessioned | 2025-04-10T10:32:37Z | |
| dc.date.available | 2025-04-10T10:32:37Z | |
| dc.description.abstract | Fingolimod (FTY-720) is the first oral medication approved by the food and drug administration (FDA) for the treatment of multiple sclerosis. It acts on the central nervous system by crossing the blood-brain barrier and binding to sphingosine-1-phosphate receptors (S1PRs). FTY-720 protects against neural damage caused by mitochondrial dysfunction and cytotoxicity by modulating S1PR1. In this study, FTY-720 was radiolabeled with technetium-99 m [Tc-99m]Tc and the biological affinity of [Tc-99m]Tc-FTY-720 was assessed using in vitro methods. The radiochemical yield and stability of [Tc-99m]Tc-FTY-720 was over 95% during 4 h. [Tc-99m]Tc-FTY-720 showed uptake on the SH-SY5Y cell line. | |
| dc.identifier.e-issn | 1588-2780 | |
| dc.identifier.issn | 0236-5731 | |
| dc.identifier.uri | http://hdl.handle.net/20.500.14701/38985 | |
| dc.language.iso | English | |
| dc.title | Radiolabeling fingolimod with technetium-99 m and evaluating its biological affinity by in vitro method | |
| dc.type | Article |